ask our doctors

Leishmaniasis

Get the facts on Leishmaniasis treatment, diagnosis, staging, causes, types, symptoms. Information and current news about clinical trials and trial-related data, Leishmaniasis prevention, screening, research, statistics and other Leishmaniasis related topics. We answer all your qestions about Leishmaniasis.

Question: Does any one know a treatment for Leishmaniasis? I worked as a DOD contractor for 13 months in IRAQ. Both of my forearms have sores that appear for several weeks then go away then return again. They are from my wrist to my elbow, the only part of me that was not covered.I am sure it is Leishmaniasis from the sand fly bites I got. Does anyone know a treatment for Leishmaniasis? I have no insurance and can't seem to find any help.

Answer: Treatment There are two common therapies containing antimony, meglumine antimoniate (Glucantim®) and sodium stibogluconate (Pentostam®). It is not completely understood how these drugs act against the parasite; they may disrupt its energy production or trypanothione metabolism. Unfortunately, in many parts of the world, the parasite has become resistant to antimony and for visceral or mucocutaneous leishmaniasis,[1] amphotericin is now the treatment of choice. Failure of AmBisome® to treat visceral leishmaniasis (Leishmania donovani) has been reported in Sudan,[2] but this failure may be related to host factors such as co-infection with HIV or tuberculosis rather than parasite resistance. Miltefosine (Impavido®), is a new drug for visceral and cutaneous leishmaniasis. The cure rate of miltefosine in phase III clinical trials is 95%; Studies in Ethiopia show that is also effective in Africa. In HIV immunosuppressed people who are coinfected with leishmaniasis it has shown that even in resistant cases 2/3 of the people responded to this new treatment. Clinical trials in Colombia showed a high efficacy for cutaneous leishmaniasis. In mucocutaneous cases caused by L.brasiliensis it has shown to be more effective than other drugs. Miltefosine received approval by the Indian regulatory authorities in 2002 and in Germany in 2004. In 2005 it received the first approval for cutaneous leishmaniasis in Colombia. Miltefosine is also currently being investigated as treatment for mucocutaneous leishmaniasis caused by L. braziliensis in Colombia,[1] and preliminary results are very promising. It is now registered in many countries and is the first orally administered breakthrough therapy for visceral and cutaneous leishmaniasis.[3](More, et al, 2003). In October 2006 it received orphan drug status from the US Food and Drug administration. The drug is generally better tolerated than other drugs. Main side effects are gastrointetinal disturbance in the 1-2 days of treatment which does not affect the efficacy. Because it is available as an oral formulation, the expense and inconvenience of hospitalisation is avoided, which makes it an attractive alternative. The Institute for OneWorld Health has developed paromomycin, results with which led to its approval as an orphan drug. The Drugs for Neglected Diseases Initiative is also actively facilitating the search for novel therapeutics. Drug-resistant leishmaniasis may respond to immunotherapy (inoculation with parasite antigens plus an adjuvant) which aims to stimulate the body's own immune system to kill the parasite.[4] Several potential vaccines are being developed, under pressure from the World Health Organization, but as of 2006 none is available. The team at the Laboratory for Organic Chemistry at the Swiss Federal Institute of Technology (ETH) in Zürich are trying to design a carbohydrate-based vaccine [6]. The genome of the parasite Leishmania major has been sequenced,[5] possibly allowing for identification of proteins that are used by the pathogen but not by humans; these proteins are potential targets for drug treatments


Leishmaniasis News